Basics of immunotherapy for epithelial ovarian cancer - 05/12/21
on behalf of
SFOG Campus
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Epithelial ovarian cancer (EOC) is the most lethal of all gynecological cancers.
Despite excellent responses to standard treatment in approximately 70% of patients, most of them will relapse within 5 years of initial treatment and many of them will develop chemotherapy-resistant disease. It is then important to find other means of treatment for these patients such as immunotherapy or targeted therapy. To understand immunotherapy, it is important to explain the dynamic interplay between cancer and the immune system. Compared to traditional tumor therapies, immunotherapy acts primarily on the immune system or the tumor microenvironment but not directly on the tumor cells, and it may also promote synergistic anti-tumor actions as part of a combined treatment. The aim of this narrative review is to provide a basic understanding of immunotherapy the interest of this treatment in EOC, and to present the main ongoing studies that could change patient management in the future
Le texte complet de cet article est disponible en PDF.Keywords : immunotherapy, epithelial ovarian cancer, immune checkpoint, tumor microenvironment
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?